Update shared on 26 Nov 2025
Fair value Decreased 0.37%Analysts have slightly reduced their price target for Fresenius Medical Care from $48.06 to $47.88, citing marginal adjustments in financial forecasts.
What's in the News
- From July 1, 2025 to September 30, 2025, Fresenius Medical Care completed the repurchase of 3,564,523 shares, representing 1.21% of shares, for €151.78 million. This was under the buyback announced on June 17, 2025. (Key Developments)
- The company provided its outlook for fiscal 2025, expecting revenue growth to be positive, with a low-single digit percent rate compared to the prior year. (Key Developments)
- Operating income, excluding special items, is projected to increase by a high-teens to high-twenties percent rate in 2025 compared to the prior year. This projection is based on constant currency and excludes special items. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased slightly, moving from $48.06 to $47.88.
- Discount Rate has fallen marginally, shifting from 5.21% to 5.11%.
- Revenue Growth projections remain virtually unchanged at 3.91%.
- Net Profit Margin is essentially the same, holding steady at approximately 6.39%.
- Future P/E Ratio shows a minor decline, changing from 11.09x to 11.02x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.